Mydecine Innovations Group (TSE:MYCO) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mydecine Innovations Group, a biotech firm focused on developing treatments for mental health disorders, has had its shares suspended from trading on the Aquis Growth Market due to non-payment of exchange fees. The company, which is pioneering next-generation medications including psychedelic compounds for conditions like PTSD and nicotine addiction, made the announcement and acknowledged its responsibility.
For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.
